Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Background: Vessel tortuosity poses a challenge during endovascular access and device delivery. Agile Devices Inc., based in Newton, Massachusetts, has developed steerable, deflectable microcatheters designed with unique soft tip deflection and excellent pushability, trackability, and torquing capabilities.
Abstract In Canada, chimeric antigen receptor (CAR) T-cell therapy was recommended for funding for the treatment of select hematological cancers. Canadian hospitals have limited experience and capacity in administrating this therapy. We conducted a qualitative interview-based study with stakeholders in Canada. Questions were asked related to the development, administration, implementation and logistical planning of CAR T-cell therapy.
Introduction Hepatocellular carcinoma (HCC) is the most prevalent type of primary liver cancer, which is predicted to be the sixth most commonly diagnosed cancer and the fourth leading cause of cancer‐related deaths worldwide 1. It is estimated that 70%–90% of patients with HCC have chronic liver disease and cirrhosis, which limits the feasibility of surgical procedures in advanced cases 2, 3.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
